Back to today’s briefing

Story perspectives

GLP-1 Drug Use Triples Among Non-Diabetics, Costing $5.8B

4/1/2025

50 9

Summary

Story summary

The use of GLP-1 receptor agonists among US adults without diabetes skyrocketed over threefold from 2018 to 2022, with 854,728 users and a staggering $5.8 billion spent annually. This dramatic rise underscores urgent conversations about the sustainability of healthcare spending and the accessibility of vital medications.

1 of 1

Story summary

The use of GLP-1 receptor agonists among US adults without diabetes skyrocketed over threefold from 2018 to 2022, with 854,728 users and a staggering $5.8 billion spent annually. This dramatic rise underscores urgent conversations about the sustainability of healthcare spending and the accessibility of vital medications.